MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.
Help employers find you! Check out all the jobs and post your resume.
